ANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Barclays

Barclays began coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report sent to investors on Tuesday,Benzinga reports. The firm issued an overweight rating and a $100.00 price objective on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings restated a “buy (b-)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 1st. JPMorgan Chase & Co. increased their price objective on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Truist Financial upped their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $99.38.

ANI Pharmaceuticals Trading Up 0.4%

Shares of ANIP opened at $81.67 on Tuesday. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $99.50. The company has a market capitalization of $1.84 billion, a P/E ratio of 50.10 and a beta of 0.48. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The firm’s 50 day simple moving average is $88.09 and its 200 day simple moving average is $80.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president owned 75,274 shares in the company, valued at approximately $6,569,161.98. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the completion of the transaction, the director directly owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 27,379 shares of company stock worth $2,417,761 over the last quarter. Company insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership purchased a new position in shares of ANI Pharmaceuticals in the third quarter valued at about $32,992,000. Balyasny Asset Management L.P. grew its stake in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $21,454,000. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the period. Finally, UBS Group AG raised its position in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.